How it works, simply
It combines GLP-1 receptor activation with GIP receptor blockade.
What the evidence tells us
Blocking GIP differs from activating it; findings from tirzepatide cannot simply be transferred to MariTide.
No study-by-study evidence summary has been verified for this profile yet. The explanation above describes its purpose and limits, not a proven benefit for every use.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
This guide does not establish a safe dose, interaction profile or long-term safety for self-use. Effects reported for one route or formulation may not apply to another.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Combines GIP-receptor antagonism with GLP-1-receptor agonism.
Sponsor or developer: Amgen
Studied or labeled topics: Obesity, Type 2 diabetes, Cardiovascular outcomes
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
Product labels and further research
These directories help locate records. They are not individual studies supporting every statement.
Readability updated October 10, 2026. Evidence review: Primary-source review pending. A wording update is not a new clinical review.